Article

34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial

2023-02-01

Abstract excerpt

Clinical outcomes for rare subtypes of relapsed gynaecological cancers (GC) including ovarian clear cell carcinomas (CCC) and carcinosarcomas (CS) are poor with limited treatment options. Preclinical data demonstrate GC with deleterious ARID1A mutations (and thus ARID1A-protein loss) display increased sensitivity to ATR inhibition. In the absence of ARID1A mutations, ATR inhibitor sensitivity can be enhanced by co...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9c7492e9-1a70-57ee-a78a-9e2408c54aa3
DOI: 10.1016/j.esmoop.2023.100814

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trialDOI 10.1016/j.esmoop.2023.100814Read

512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignanciesSemantic proximity Read

Translational genomics of ovarian clear cell carcinoma.Semantic proximity Read

ARID1A in Gynecologic Precancers and Cancers.Semantic proximity Read

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaSemantic proximity Read

Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.Semantic proximity Read

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer modelsSemantic proximity Read

Targeting DNA Damage Response Pathway in Ovarian Clear Cell CarcinomaSemantic proximity Read

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Semantic proximity Read

Deciphering the Pleiotropic Role of ARID1a and RIF1 in Endometrioid Ovarian Cancer.Semantic proximity Read

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.Semantic proximity Read

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.Semantic proximity Read

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1ASemantic proximity Read